IASO Bio Announces NMPA IND Approval for IASO208, Advancing Its In Vivo CAR-T Platform into Synchronized U.S.-China Clinical Development

First lentiviral-vector-based in vivo CAR-T product from China to receive a U.S. FDA IND clearance; a Phase Ib study in R/R B-NHL will be initiated directly in the United States SHANGHAI, NANJING, China, and PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.